Rasna Therapeutics (RASP) 10-Q 15 May 19 2019 Q2 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	6 Months Ended
	Mar. 31, 2019	May 08, 2019
Document And Entity Information [Abstract]
Entity Registrant Name	Rasna Therapeutics Inc.
Entity Central Index Key	0001582249
Trading Symbol	RASP
Amendment Flag	false
Document Type	10-Q
Current Fiscal Year End Date	--09-30
Document Period End Date	Mar. 31, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Small Business	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		68,908,003

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Current assets:
Cash and cash equivalents	$ 42,413	$ 42,693
Prepayments and other receivables	43,498	66,936
Related party receivable	76,900	237,866
Total current assets	162,811	347,495
Property and equipment, net	2,767	5,420
Intellectual property	236,269	236,269
In-process research and development	613,100	613,100
Indefinite lived intangible asset	1,300,000	1,300,000
Goodwill	2,722,985	2,722,985
Total non-current assets	4,875,121	4,877,774
Total assets	5,037,932	5,225,269
Current liabilities:
Accounts payable and accrued expenses	1,582,768	1,421,655
Related parties payable	550,000	550,000
Convertible note payable	245,485	137,340
Total current liabilities	2,378,253	2,108,995
Taxes payable		10,618
Total liabilities	2,378,253	2,119,613
Commitments and Contingencies (Note 9)
Shareholders' equity
Common stock, $0.001 par value, respectively; 200,000,000 shares authorized, of which 68,908,003 are issued and outstanding.	68,909	68,909
Additional paid-in capital	19,632,863	19,412,176
Accumulated deficit	(17,042,093)	(16,375,429)
Total shareholders' equity	2,659,679	3,105,656
Total liabilities and shareholders' equity	$ 5,037,932	$ 5,225,269

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (PARENTHETICAL) - $ / shares	Mar. 31, 2019	Sep. 30, 2018
Statement of Financial Position [Abstract]
Common stock, par value (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	200,000,000	200,000,000
Common stock, shares issued (in shares)	68,908,003	68,908,003
Common stock, shares outstanding (in shares)	68,908,003	68,908,003

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
Income Statement [Abstract]
Revenue
Cost of revenue
Gross profit
Operating expenses:
General and administrative	198,942	824,950	383,507	1,698,751
Research and development		32,582	75,000	209,514
Consultancy fees third parties and related parties	11,977	62,866	41,195	554,410
Legal and professional fees	52,371	216,319	162,916	392,967
Total operating expenses	263,290	1,136,717	662,618	2,855,642
Loss from operations	(263,290)	(1,136,717)	(662,618)	(2,855,642)
Other expense:
Foreign currency transaction loss	(2,070)	(7,695)	(4,046)	(11,371)
Total other expense	(2,070)	(7,695)	(4,046)	(11,371)
Loss from operations before income taxes	(265,360)	(1,144,412)	(666,664)	(2,867,013)
Income tax provision
Net loss	$ (265,360)	$ (1,144,412)	$ (666,664)	$ (2,867,013)
Basic and diluted loss per share attributable to common shareholders (in dollars per share)	$ 0	$ (0.02)	$ (0.01)	$ (0.04)
Basic and diluted weighted average common shares outstanding (in shares)	68,908,003	68,908,003	68,908,003	68,908,003

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS’ EQUITY (UNAUDITED) - USD ($)	Total	Common Stock	Additional Paid-In Capital	Accumulated Deficit
Balance at Sep. 30, 2017	$ 6,037,736	$ 68,909	$ 18,267,895	$ (12,299,068)
Balance (in shares) at Sep. 30, 2017		68,908,003
Share based compensation	467,623		467,623
Warrants issued for consulting services	522,350		522,350
Net Loss	(2,867,013)			(2,867,013)
Balance at Mar. 31, 2018	4,160,696	$ 68,909	19,257,868	(15,166,081)
Balance (in shares) at Mar. 31, 2018		68,908,003
Balance at Sep. 30, 2018	$ 3,105,656	$ 68,909	19,412,176	(16,375,429)
Balance (in shares) at Sep. 30, 2018	68,908,003
Share based compensation	$ 220,687		220,687
Warrants issued for consulting services
Net Loss	(666,664)			(666,664)
Balance at Mar. 31, 2019	$ 2,659,679	$ 68,909	$ 19,632,863	$ 17,042,093
Balance (in shares) at Mar. 31, 2019		68,908,003

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (UNAUDITED) - USD ($)	6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net Loss	$ (666,664)	$ (2,867,013)
Adjustments to reconcile net loss to net cash used in operating activities:
Share based compensation	220,687	467,623
Warrants issued for consulting services		522,350
Depreciation	2,654	3,117
Other non-cash items	8,145
Related party receivable write off		28,931
Changes in operating assets and liabilities:
Prepayments and other receivables	23,438	(23,330)
Related party receivable	160,967
Accounts payable and accrued expenses	150,493	(125,823)
Net cash used in operating activities	(100,280)	(1,994,145)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchase of property, plant and equipment		(4,073)
Net cash used in investing activities		(4,073)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of shares of common stock
Proceeds from issuance of convertible note payable	100,000
Net cash provided by financing activities	100,000
Effect of foreign exchange rate
Net increase/(decrease) in cash and cash equivalents	(280)	(1,998,218)
Cash and cash equivalents, beginning of period	42,693	2,537,611
Cash and cash equivalents, end of period	$ 42,413	$ 539,393

GENERAL INFORMATION

GENERAL INFORMATION	6 Months Ended
	Mar. 31, 2019
GENERAL INFORMATION [Abstract]
GENERAL INFORMATION	1 GENERAL INFORMATION Rasna Therapeutics, Inc. (“Rasna DE" or "Rasna Inc.”), is a company incorporated in the State of Delaware on March 28, 2016. On October 11, 2017, the Company changed its fiscal year end from March 31 to September 30 and filed a Form 10-KT on November 30, 2017. On April 27, 2016, Rasna Therapeutics Limited, a private limited company incorporated in England and Wales under the U.K. Companies Act (“Rasna UK”) sold its stake in Falconridge Holdings Limited, or Falconridge, to Rasna DE for $ 1. This entity had no operations, no assets or liabilities as of this date. On May 17, 2016, Rasna DE and its subsidiary Falconridge entered into an Agreement of Merger and Plan of Reorganization (“Merger Agreement”) with Arna Therapeutics Limited, a British Virgin Islands company, or Arna, which was a clinical stage biotechnology company focused on drugs to treat diseases in oncology and immunology, mainly focusing on the treatment of leukemia. Pursuant to the agreement, Arna was merged into Falconridge and the shareholders of Arna were issued shares of Rasna DE in exchange for shares of Arna. On August 15, 2016, Active With Me, Inc., or AWM, entered into an Agreement of Merger and Plan of Reorganization (the “Merger Agreement”) with Rasna DE, and Rasna Acquisition, providing for the merger of Rasna Acquisition with and into Rasna DE, (the “Merger”), with Rasna DE, surviving the Merger as a wholly-owned subsidiary of AWM. Rasna Therapeutics, Inc., is a biotechnology company that is engaged in modulating the molecular targets NPM 1 1 The Merger has been treated as a reverse recapitalization effected by a share exchange for financial accounting and reporting purposes since substantially all of AWM’s operations were disposed of prior to the consummation of the transaction. Rasna DE is treated as the accounting acquirer as its shareholders control the Company after the Merger and AWM was the legal acquirer. As a result, the assets and liabilities and the historical operations that are reflected in the financial statements are those of Rasna DE as if Rasna DE had always been the reporting company. Since AWM had no operations upon the Merger Agreement taking place, the transaction was treated as a reverse recapitalization for accounting purposes and no goodwill or other intangible assets were recorded by the Company as a result of the Merger Agreement. These financial statements are presented in United States dollars (“USD”) which is also the functional currency of the primary economic environment in which the Company operates. See Note 2

ACCOUNTING POLICIES

ACCOUNTING POLICIES	6 Months Ended
	Mar. 31, 2019
ACCOUNTING POLICIES [Abstract]
ACCOUNTING POLICIES	2 ACCOUNTING POLICIES The principal accounting policies applied in the preparation of these unaudited condensed consolidated financial statements are set out below. These policies have been applied consistently to all the periods presented unless otherwise stated. Basis of preparation These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (the "SEC”) and United States generally accepted accounting principles (“GAAP”) for interim reporting. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended September 30, 2018 Principles of Consolidation In accordance with Accounting Standards Codification ("ASC") 810 Consolidation, the Company consolidates any entity in which it has a controlling financial interest. Further, the Company consolidates any variable interest entity that it is deemed to be the primary beneficiary of, and for which the Company has the power to direct its significant activities. Upon review of the relationship between Rasna Therapeutics Limited (“Rasna UK”) and Rasna Inc., Management noted that equity investment in Rasna UK was not sufficient to fund its operations. Accordingly, Rasna Inc. was considered to be the primary beneficiary of the assets held within Rasna UK, which primarily consist of cash received from Rasna Inc. to fund its operations, and for which the Company has the power to direct its significant activities. As a result, Rasna Inc. consolidates this variable interest entity, which has minimal activity and is in the process of being liquidated. The consolidated financial statements include the financial statements of the Company and its subsidiary, Arna Therapeutics Limited and its variable interest entity, Rasna Therapeutics Ltd, as well as the operations of Rasna Inc. for the period from May 17, 2016 through March 31, 2019 All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements. Business Combinations Management accounts for business combinations under the provisions of ASC Topic 805 10 805 10 805 10 The amounts reflected within Note 3 are the results of the final valuation report of the purchase price allocation. Going Concern The Company is subject to a number of risks similar to those of other pre-commercial stage companies, including its dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with research, development, testing, and obtaining related regulatory approvals of its pipeline products, suppliers and collaborators, successful protection of intellectual property, competition with larger, better-capitalized companies, successful completion of the Company's development programs and, ultimately, the attainment of profitable operations are dependent on future events, including obtaining adequate financing to fulfill its development activities and generating a level of revenues adequate to support the Company's cost structure. The Company has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and at March 31, 2019 , had an accumulated deficit of $17,042,093, a net loss for the six months ended March 31, 2019 of $666,664 and net cash used in operating activities of $100,280. We expect to continue to incur net losses and have significant cash outflows for at least the next 12 In the event that the Company is unable to secure the necessary additional cash resources needed, the Company may slow current development phases or halt new development phases in order to mitigate the effects of the costs of development. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company's assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company's cost structure. Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the fair values of stock based awards, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the consolidated financial position and results of operations. Fair Value The carrying value of the Company’s financial instruments, including cash and cash equivalents, related party balances, accounts payable and accrued liabilities, approximate fair value because of the short-term nature of such financial instruments. Management measures certain other assets at fair value on a nonrecurring basis when they are deemed to be other-than-temporarily impaired. Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of related party receivables. Deposits held with banks, including those held in foreign branches of global banks, may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and bear minimal risk. Management believes that the institutions that hold our instruments are financially sound and are subject to minimal credit risk. Cash and Cash Equivalents The Company considers all short-term investment with an original maturity of three March 31, 2019 September 30, 2018 42,413 and $ respectively. Property and Equipment Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed in a straight line method based on the estimated useful lives of the related assets. The estimated useful lives of the major classes of depreciable assets are 3 year s for property and equipment Goodwill and Intangible assets Intangible assets are made up of indefinite lived intangible assets, in-process research and development, (“IPR&D”) and certain intellectual property (“IP”). The balance of the indefinite lived intangible assets represents the platform technology that was acquired in 2013 (see Note 3 - Acquisitions) n ha Goodwill represents the premium paid over the fair value of the net tangible and intangible assets acquired in business combinations. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the asset might be impaired. An impairment charge is recognized only when the implied fair value of the Company’s reporting unit’s goodwill is less than its carrying amount. Management evaluates indefinite life intangible assets for impairment on an annual basis and on an interim basis if events or changes in circumstances between annual impairment tests indicate that the asset might be impaired. The ongoing evaluation for impairment of its indefinite life intangible assets requires significant management estimates and judgment. Management reviews indefinite life intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. There were no impairment charges during the six months ended March 31, 2019 2018 Risks and Uncertainties The Company intends to operate in an industry that is subject to rapid change. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks associated with an early stage company, including the potential risk of business failure. Research and development Expenditure for research and development are charged to the statements of operations in the year in which it is incurred with the exception of expenditures incurred in respect of the development of major new products where the outcome of those projects is assessed as being reasonably certain in regards to viability and technical feasibility. Such expenditure is capitalized and amortized straight line over the estimated period of sale for each product, commencing in the year that sales of the product are first made. To date, the Company has not capitalized any such expenditures other than certain IPR&D & IP recorded in connection with certain acquisition or equity transactions. Foreign Currency Items included in the financial statements are measured using their functional currency, being the currency of the primary economic environment in which the company operates. The financial statements are presented in United States Dollar (“USD”), which is the company’s functional and presentational currency. Foreign currency transactions are translated using the rate of exchange applicable at the date of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-translation at the year-end of monetary assets and liabilities denominated in foreign currencies are recognized in the statements of operations. Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The following table sets forth potential common shares issuable upon the exercise of outstanding options and the exercise of warrants, all of which have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: March 31, 2019 March 31, 2018 Stock options 4,076,675 4,829,875 Warrants 1,926,501 1,926,501 Total shares issuable upon exercise or conversion 6,003,176 6,756,376 The following is the computation of net loss per share for the following periods: For the Three Months Ended March 31, 2019 2018 (Unaudited) (Unaudited) Net loss for the period $ (265,360 ) $ (1,144,412 ) Weighted average number of shares 68,908,003 68,908,003 Net loss per share (basic and diluted) $ (0.00 ) $ (0.02 ) For the Six Months Ended March 31, 2019 2018 (Unaudited) (Unaudited) Net loss for the period $ (666,664 ) $ (2,867,013 ) Weighted average number of shares 68,908,003 68,908,003 Net loss per share (basic and diluted) $ (0.01 ) $ (0.04 ) Warrants In April 2016, the Company committed to issue warrants as compensation to the placement agents relating to fundraising. On February 28, 2017, the Company issued a ten year warrant to purchase 1,440,501 shares of common stock at an exercise price of $0.37 per share. The Company had determined that the service inception date preceded the grant date, and accordingly, recorded a liability to issue warrants in the Company as of the date that the equity was issued, with an offset charge to additional paid-in capital as these are offering costs. The liability to issue warrants was marked to market each period until the grant date, at which point the Company determined that in accordance with ASC 815-40-25- 7 7 - Warrants In July 2017, the Company committed to issue warrants as compensation to the placement agents relating to fundraising. On August 31, 2017, the Company issued a ten year warrant to purchase 112,000 shares of common stock at an exercise price of $0.65 per share. On August 31, 2017, the Company entered into consulting agreements with placement agents who were providing consulting services in the areas of capital market advisory and investor relations. In lieu of fees for these consulting services, on September 1, 2017, the Company issued ten year warrants to purchase 374,000 shares of common stock at an exercise price of $0.60 per share. The Company determined that the service inception date did not precede the grant date, and accordingly classifies the warrants in shareholders' equity, in accordance with ASC 815-40-25- 7 7 Equity-Based Payments ASC Topic 718 The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505 50 Income taxes On December 22, 2017, The Tax Cuts and Jobs Act was signed into law and has resulted in significant change to the U.S corporate income tax system. These changes include a federal statutory rate reduction from Changes in tax rates and tax laws are accounted for in the period of enactment. D uring the six March 31, 2019 2017 Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017 1 805 The Company adopted ASU 2017 01 In January 2017, the FASB issued ASU 2017 04 350 two An entity will apply a one The guidance is effective for annual and interim goodwill impairment tests performed for periods beginning after December 15, 2019 with early adoption permitted in January 2017. The Company is currently evaluating the impact of adopting this guidance In July 2017, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2017 11 260 480 815 1 815 2 260 In August, 2016, the FASB issued ASU 2016 15 320 2016 15 eight 2016 15 In May 2017, The FASB issued ASU 2017 09 718 2017 09 2017 09 2017 09 In June 2018, the FASB issued ASU 2018 - 07 , Compensation - Stock Compensation (Topic 718 718 , to include share-based payment transactions for acquiring goods and services from nonemployees. Some of the areas for simplification apply only to nonpublic entities. The amendments specify that Topic 718 apply to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments in A SU 2018 - 07 also clarify that Topic 718 does not apply to share-based payments used to effectively provide ( 1 ) financing to the issuer or ( 2 ) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606 , Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. We do not plan to early adopt this ASU. We are currently evaluating the potential impacts of this updated guidance, and do not expect the adoption of this guidance to have a material impact on our consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018 13 820 2018 13

ACQUISITIONS

ACQUISITIONS	6 Months Ended
	Mar. 31, 2019
ACQUISITIONS [Abstract]
ACQUISITIONS	3 ACQUISITIONS The following transactions were accounted for using the acquisition accounting method which requires, among other things, that the assets acquired and liabilities assumed are recognized at their acquisition date fair value. On May 5, 2016, Rasna UK sold its intellectual property to Falconridge, a subsidiary of Rasna, for a note payable in the amount of $236,269. Rasna UK is considered a VIE and consolidated in these financial statements, however, is not an entity under common control as Rasna controlled both Falconridge and Rasna UK at the time of the transaction, this transaction eliminates on consolidation. On May 17, 2016, Rasna and its subsidiary Falconridge entered into an Agreement of Merger and Plan of Reorganization with Arna. Pursuant to the agreement, Arna was merged into Falconridge and the shareholders of Arna were issued shares of Rasna in exchange for shares of Arna. Arna was deemed to be the accounting acquirer because Rasna and Falconridge Holdings Limited were non-trading holding companies and Arna’s operations will comprise the ongoing operations of the combined entity and its senior management will serve as the senior management of the combined entity. Further, 65% of the voting interest in Rasna was acquired by Arna shareholders in connection with the transaction. Therefore, the assets and liabilities of the acquired entity, Rasna, were written to fair value in accordance with the Acquisition Method prescribed in ASC 805 The consideration transferred was measured based upon the share price recently received during a non-public equity raise in Rasna, during which non-related investors paid $0.40 per share of common stock. During the acquisition transaction, 19,187,500 of 54,837,790 shares were issued to legacy Rasna shareholders, which results in consideration transferred to the acquiree’s shareholders of $7,675,000. In addition, $607,159 of a related party receivable due to Arna from Rasna UK, was forgiven as part of the consideration transferred. The purchase price allocation as of the date of acquisition is set forth in the table below. As per the purchase accounting method, the tangible and identifiable intangible assets acquired and liabilities assumed were recorded at fair value as of the date of acquisition, with the remaining purchase price recorded as goodwill. The Company’s allocation of the purchase price in connection with the acquisition was calculated as follows: Balance as of May 17, 2016 Share consideration transferred $ 7,675,000 Forgiveness of receivable 607,159 Consideration transferred $ 8,282,159 Less: Fair value of assets acquired Cash and cash equivalents (5,116,609 ) Other receivables (14,187 ) Prepayment (66,856 ) Related party receivables (20,412 ) Intellectual property (236,269 ) In-Process research and development (613,100 ) Plus: Liabilities assumed Accounts payable and accrued expenses 492,603 Related party payables 15,656 Goodwill $ 2,722,985 Of the above assets acquired and liabilities assumed, the intellectual property acquired was owned by Falconridge and the residual assets acquired and liabilities assumed comprised the VIE that was controlled by Rasna, Inc. Acquired In-Process Research and Development Acquired IPR&D is the fair value of the LSD- 1 1 $613,100 as of the acquisition date using the cost approach. This was based on the fact that LSD- 1 The Company retained a Clinical Research Organisation ("CRO") to perform all related research and development associated with LSD- 1 1 1 1 Active With Me, Inc. On August 15, 2016, Active With Me, Inc., entered into an Agreement of Merger and Plan of Reorganization (the “Merger Agreement”) with Rasna, Inc., and Rasna Acquisition Corp., a Delaware corporation and a wholly owned subsidiary of Active With Me, Inc. (“Merger Sub”), providing for the merger of Merger Sub with and into Rasna, Inc. (the “Merger”), with Rasna, Inc. surviving the Merger as a wholly-owned subsidiary of Active With Me, Inc. As a result of the Merger, the resulting company, Rasna Therapeutics, Inc., is a biotechnology company that is engaged in modulating the molecular targets NPM 1 1 The Merger was treated as a reverse recapitalization effected by a share exchange for financial accounting and reporting purposes since substantially all of Active With Me’s operations were disposed of prior to the consummation of the transaction. Rasna Successor is treated as the accounting acquirer as its shareholders control the Company after the Exchange Agreement, even though Active With Me, Inc. was the legal acquirer. As a result, the assets and liabilities and the historical operations that are reflected in these financial statements are those of Rasna Successor as if Rasna Successor had always been the reporting company. Since Active With Me, Inc. had no operations upon the Merger Agreement taking place, the transaction was treated as a reverse recapitalization for accounting purposes and no goodwill or other intangible assets were recorded by the Company as a result of the Merger Agreement. Thereafter, pursuant to a Stock Purchase Agreement, the Company transferred all of the outstanding capital stock of Rasna Successor to a former officer and director of Active With Me, Inc. in exchange for cancellation of an aggregate of 1,500,000 shares of Rasna Successor’s common stock held by such person. In connection with the share exchange, each share of Rasna, Inc. was exchanged for the right to receive .33 shares in Active With Me, Inc. Once issued, the new shares were combined with the 3,305,000 common shares held by legacy Active With Me, Inc. shareholders. Immediately following the Merger, 1,500,000 shares were canceled, which related to one legacy Active With Me shareholder that effectively spun off the remaining assets of Active With Me in connection with the transaction. Finally, subsequent to the transaction, the legal acquirer executed a 3.25 for 1 stock split on its common shares. Following the closing of the Merger and Rasna Successor’s cancellation of 1,500,000 shares in the Split-Off, there were 19,901,471 shares of Rasna Successor issued and outstanding, which once effected for the 3.25 for 1 64,679,798 shares outstanding in the combined entity.

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS	6 Months Ended
	Mar. 31, 2019
GOODWILL AND INTANGIBLE ASSETS [Abstract]
GOODWILL AND INTANGIBLE ASSETS	4 GOODWILL AND INTANGIBLE ASSETS As noted in Note 3 on May 17, 2016, there was a transaction where the Company acquired an entity and, at initial purchase price, it was determined that there was $236,269 of intellectual property, $613,100 of In-process research and $2,722,985 of goodwill. Goodwill Goodwill represents the excess of the purchase price over the fair value of net assets acquired in business combinations accounted for under the purchase method of accounting. The following table summarizes the Company’s goodwill for the periods indicated resulting from the acquisitions by the Company: March 31, September 30, 2019 2018 Goodwill $ 2,722,985 $ 2,722,985 The Company performed an impairment analysis and no impairment was determined. Therefore no impairment was recorded as of March 31, 2019 September 30, 2018 Intangible Assets On December 17, 2013 the Company’s shareholder, Panetta Partners Limited, transferred 5,000,000 of its shares in Arna Therapeutics Limited to Eurema Consulting S.r.l. and 5,000,000 shares in Arna Therapeutics Limited to TES Pharma S.r.l. In exchange for the shares, Panetta Partners Limited obtained intellectual property ("Platform Technology") from TES Pharma S.r.l and Eurema Consulting S.r.l. Panetta Partners Limited then assigned the Platform Technology to Arna Therapeutics Limited, which was accounted for as a capital contribution. The fair value of the shares exchanged for the IPR&D was $0.13 per share; in addition the issue price for shares in October 2013 was $0.13 per share (shares issued post acquisition of the IPR&D were issued at $0.28) and accordingly the Company valued the Platform Tech nology at $1.3 million. IPR&D relating to LSD- 1 1 100,002 Euros for costs incurred to date and to perform research and development on a going forward basis. Additionally, the Company entered into an amended license agreement whereby Rasna agreed to pay TTFactor an additional 435,000 Euros as of May 17, 2016, regarding services rendered between September 9, 2014 to May 17, 2016. Based on the cost approach, the IPR&D was valued at $613,100. At the time of the acquisition, the Company had reasonably expected to use the Platform Technology, in the asset’s then current state, in two independent research projects that had not commenced as of the date of the acquisition. The Company’s research projects applied the conclusions reached in the Platform Technology to develop treatments for AML through reformulation of certain available pharmaceuticals and independent development of a new pharmaceutical treatment. Both research projects were initiated shortly after the Platform Technology was acquired and continue through the date of the financial statements. At the time of acquisition, and at present, no legal, regulatory, contractual, competitive, economic, or other factors were present that would constrain the useful life of the asset to the Company. The agreement to purchase the asset has no provisions that would limit the timeframe of use, legally, contractually or economically, and the asset remains a competitive platform for results in the treatment of Acute Myeloid Leukemia and lymphoma. Specifically, the agreement irrevocably assigns all rights and title to the Asset, without limitation or contingencies. No limitations or alternative technology has emerged that would suggest obsolescence or a change in the competitive landscape for the Platform Technology as of the most recent reporting period. In addition, the Company has concluded that the useful life of the Platform Technology at the time of acquisition was beyond a foreseeable horizon, and therefore the asset is classified as an indefinite lived intangible asset. The IPR&D and intellectual property are considered to have an indefinite life and there were no impairment charges recognized during the six months ended March 31, 2019 the period ended September 30, 2018 The following table summarizes the Company’s intangible assets as of the following periods: March 31, September 30, 2019 2018 Estimated (Unaudited) Useful Life In-process research and development $ 613,100 $ 613,100 Indefinite Intellectual Property 236,269 236,269 Indefinite Indefinite lived intangible asset 1,300,000 1,300,000 Indefinite $ 2,149,369 $ 2,149,369

ACCOUNTS PAYABLE AND ACCRUED EX

ACCOUNTS PAYABLE AND ACCRUED EXPENSES	6 Months Ended
	Mar. 31, 2019
ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]
ACCOUNTS PAYABLE AND ACCRUED EXPENSES	5 ACCOUNTS PAYABLE AND ACCRUED EXPENSES The following table summarizes the Company’s accounts payable and accrued expenses as of the following periods: March 31, 2019 (Unaudited) September 30, 2018 Accounts payable $ 829,903 $ 719,830 Accrued expenses 752,865 701,825 $ 1,582,768 $ 1,421,655 Accounts payable is predominantly made up of unpaid invoices relating to research and development, accounting and professional f ees. Included within the accrued expenses balance of $752,865 at March 31, 2019 ely $ 268,000 relating to vendors for research and development expenses, $202,000 rela ting to an accrual for directors fees, approximately $22,000 relating payroll accruals, approximately $146,000 related to consultancy and legal expenses, approximately $44,000 related of travel expenses incurred on the Company credit card, and approximately $71,000 of other accrued costs. Included within the accrued expenses balance of $701,825 at September 30, 2018 $72,000 of accrued legal, accounting and professional fees, $193,000 of research and development fees, $22,000 for payroll related expenses, $165,000 for Directors fees, $155,000 for Consultancy and legal fees, $39,000 for credit card expenses and $55,000 for patent related expenses.

STOCK-BASED COMPENSATION

STOCK-BASED COMPENSATION	6 Months Ended
	Mar. 31, 2019
STOCK-BASED COMPENSATION [Abstract]
STOCK-BASED COMPENSATION	6 STOCK-BASED COMPENSATION 2016 On July 19, 2016, the Company adopted its 2016 one 9,750,000 shares of the Company’s common stock was authorized for issuance with respect to awards granted under the Equity Incentive Plan. Stock-based compensation expense is the estimated fair value of options granted amortized on a straight-line basis over the requisite service period for the entire portion of the award less an estimate for anticipated forfeitures. The Company uses the “simplified” method to estimate the expected term of the options because the Company’s historical share option exercise experience does not provide a reasonable basis upon which to estimate expected term. No six ended March 31, 2019 2018 The Black-Scholes option pricing model was developed for use in estimating the fair value of traded options, which have no vesting restrictions and are fully transferable. In addition, option valuation models require the input of highly subjective assumptions including the expected stock price volatility. Because our stock options have characteristics significantly different from those of traded options, and because changes in the subjective input assumptions can materially affect the fair value estimate, in management's opinion, the existing models do not necessarily provide a reliable single measure of the fair value of our stock options. The following table summarizes stock option activity for the three months ended March 31, 2019 Number of Options Weighted Average Exercise Price Per Option Weighted Average remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding balance at September 30, 2018 4,819,875 0.55 7.27 $ 589,837 Granted — — — — Exercised — — — — Forfeited and Expired (743,200 ) (0.30 ) — — Outstanding balance at March 31, 2019 4,076,675 0.59 6.87 $ — Options exercisable at March 31, 2019 2,539,796 0.40 6.2 $ — As of March 31, 2019 , there was approximately $342,523 of total unrecognized compensation cost related to stock options. The cost is expected to be recognized over a weighte d average period 0.58 years. For the three six months ended March 31, 2019 $107,140 and $226,157 related to share based compensation to directors and employees respectively, has been included within the general and administrative expense category in the unaudited condensed consolidated interim financial statements. An additional $( 14,689) 5,470) For the three six months ended March 31, 2018 $240,050 and $492,959 related to share based compensation to directors and employees respectively, has been included within the general and administrative expense category in the unaudited condensed consolidated interim financial statements. An additional $0 and ( $31,471 ) related to non-employees respectively, has been included within the consultancy fees third parties and related parties expense category in the unaudited condensed consolidated interim financial statements.

WARRANTS

WARRANTS	6 Months Ended
	Mar. 31, 2019
WARRANTS [Abstract]
WARRANTS	7 WARRANTS On April 10, 2016, the Company incurred the obligation to issue warrants to placement agents relating to fundraising. The Company accounted for the obligation based on an estimate of the fair value of warrants issued using the Black-Scholes options pricing model and the Company recorded $484,009 as a liability and a reduction to proceeds of the equity offering (additional paid-in-capital). The Company assessed the fair value for each reporting period of the liability and recorded changes to additional paid-in capital. At February 28, 2017, the date the warrants were issued, the obligation was reversed to additional paid-in capital and no outstanding liability existed. Based upon the Company’s analysis of the criteria contained in ASC Topic 815 40 On July 3, 2017, the Company entered into a finder's agreement with a placement agent whereby they incurred an obligation to issue warrants once a private placement has successfully been entered into. On August 31, 2017, the performance condition had been satisfied and the Company issued the related warrants. Based upon the Company’s analysis of the criteria contained in ASC Topic 815 40 On September 1, 2017, the Company issued warrants to placement agents in lieu of fees for consultancy services to be provided over a period of 6 months. Based upon the Company’s analysis of the criteria contained in ASC Topic 815 40 The Company accounted for the obligation based on an estimate of the fair value of warrants issued using the Black-Scholes option pricing model. The Company accounted for the obligation based on an estimate of the fair value of warrants issued using the Black-Scholes option pricing model. The following table summarizes warrant activity for the six months ended March 31, 2019 Number of Warrants Weighted Average Exercise Price Per Option Weighted Average remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding balance at September 30, 2018 1,926,501 — — 6,875,819 Granted — — — — Forfeited — — — — Outstanding balance at March 31, 2019 1,926,501 — — $ 6,875,819 Warrants exercisable at March 31, 2019 — — — $ — The performance related warrants issued on August 31, 2017 are fully vested and do not have any forfeiture conditions attached. During the three and six months ended March 31, 2019 costs were recognized for consultancy related warrants.

CONVERTIBLE NOTE

CONVERTIBLE NOTE	6 Months Ended
	Mar. 31, 2019
Debt Disclosure [Abstract]
CONVERTIBLE NOTE	8 . On August 8, 2018, the Company entered into a 12% Convertible Promissory Note with High Octane Bioresearch Ltd. (the “Holder”) pursuant to which the Company issued a Convertible Promissory Note to the Holder. The Holder provided the Company with $135,000 in cash, which was received by the Company during the period ended September 30, 2018 On October 19, 2018, the Company entered into a second 12 % Convertible Promissory Note with the Holder with a maturity date of October 19, 2019. The Holder provided the Company with $ 100,000 At March 31, 2019

RELATED PARTY TRANSACTIONS

RELATED PARTY TRANSACTIONS	6 Months Ended
	Mar. 31, 2019
RELATED PARTY TRANSACTIONS [Abstract]
RELATED PARTY TRANSACTIONS	9 . RELATED PARTY TRANSACTIONS During the normal course of its business, the Company enters into various transactions with entities that are both businesses and individuals. The following is a summary of the related party transactions during the three months ended March 31, 2019 and 2018 Eurema Consulting Eurema Consulting S.r.l. is a significant shareholder of the Company. During the three six months ended March 31, 2019 March 31, 2018 March 31, 2019 September 30, 2018 Gabriele Cerrone Gabriele Cerrone is affiliated with one three six March 31, 2019 March 31, 2018 March 31, 2019 September 30, 2018 175,000 for past consultancy services. Roberto Pellicciari and TES Pharma Roberto Pellicciari is the majority shareholder of TES Pharma Srl, one three six March 31, 2019 March 31, 2018 March 31, 2019 September 30, 2018 for past consultancy services. Alessandro is the chairman of Therapeutics . and also serves on the Board of Directors of TES , one of the Company's suppliers. At March 31, 2019 and September 30, 2018 75,000 75,000 Tiziana Life Sciences Plc ("Tiziana") As at March 31, 2019 and September 30, 2018 $ 252,746 s of the date these financials are issued, the related party receivable has been fully collected. 10 Panetta Partners Panetta Partners Limited, a shareholder of Arna, is a company in which Gabriele Cerrone has significant interest and also serves as a director. At March 31, 2019 September 30, 2018 There is no interest charged on the balances with related parties. There are no defined repayment terms and such amounts can be called for payment at any time.

COMMITMENTS AND CONTINGENCIES

COMMITMENTS AND CONTINGENCIES	6 Months Ended
	Mar. 31, 2019
COMMITMENTS AND CONTINGENCIES [Abstract]
COMMITMENTS AND CONTINGENCIES	10. COMMITMENTS AND CONTINGENCIES License Agreements In November 2016, the Company entered into a license agreement with Profs. Falini and Martelli, wherein it obtained the exclusive rights related to the use or reformulation of Actinomycin D and intends to utilize these rights for the development of new product. In connection with this agreement, the Company was committed to paying milestone payments, the first being a EUR 50,000 payment to be paid six months after the agreement was signed. The payment was made to Profs. Falini and Martelli in June 2017. The specific timing of the remaining milestones cannot be predicted and depends upon research and clinical developments. None of the milestones have been reached as at the date of these unaudited financial statements. Lease Agreements In February 2018, the Company renewed its lease agreement with the same terms, with Bucks County Biotechnology Centre Inc. in Doylestown Pennsylvania, where certain employees of the Company are based. The lease provides for annual basic lease payments from February 1, 2019 to January 31, 2020 of $13,480, plus and utility expense estimate of $ 237 per month. During the six months March 31, 2019 , the Company incurred approximately $8,000 of rental expenses related to this agreement. Consultancy Agreements In October 2016, the Company entered into a consultancy agreement with Tiziano Lazzaretti in which he agreed to serve as Chief Financial Officer for a fee of $50,000 per year. This was increased to $80,000 a year in April 2017 by the Company's compensation committee. During the six months March 31, 2019 the Company had incurred approximately $20,000 March 31, 2019 Employment Agreements On May 24, 2017, the Company entered into an executive employment agreement with Kunwar Shailubhai to serve as Chief Executive Officer and Chief Scientific Officer for a remuneration of $300,000 per annum. Also included within the agreement is a performance related bonus of 35% of base salary. Based on Board discretion, it is not probable that this bonus will be paid out for the period October 1, 2017 to March 31, 2019 March 31, 2019 During the three and six ended March 31, 2019 , the Company had incurred no salary expenses related to this appointment due to the shared services waiver detailed below. In June 2017, the board of directors awarded Dr Shailubhai 1,700,000 options to vest over a 4 year period, with an exercise price of $0.85 and a fair value at grant date of $985,081. During the three and six months ended March 31, 2019 the Company had incurred $69,576 and $140,700 respectively In January 2019, the decision was taken to terminate all employment contracts in . effective January 16, 2019. This was to reflect the fact that employees were spending an increasing amount of time working on Life Sciences PLC. Moving forward, any time spent on activities will be charged by Life Sciences PLC under the shared services agreement detailed below. Shared Services Agreement The Company has entered into a shared services agreement with Tiziana Life Sciences Plc. Under the terms of this agreement, the Company will be charged for shared services including payroll and rent for the Lexington Avenue premises, on a monthly basis based on allocated costs incurred. This agreement is effective from January 1, 2017. At March 31, 2019 $76,900 is due from Tiziana Life Sciences PLC. Tiziana has agreed to waive all charges for shared services from October 2018 onwards, until further notice. Other Commitments The Company may enter into certain licensing agreements for products currently under development. The Company may be obligated in future periods to make additional payments, which would become due and payable only upon the achievement of certain research and development, regulatory, and approval milestones. The specific timing of such milestones cannot be predicted and depend upon future discretionary research and clinical developments, as well as, regulatory agency actions. Further, under the terms of certain agreements the Company may be obligated to pay commercial milestones contingent upon the realization of sales revenues and sublicense revenues. Due to the long range nature of such commercial milestones, they are neither probable at this time nor predictable, and consequently are not considered contingent milestone payment amounts.

SUBSEQUENT EVENTS

SUBSEQUENT EVENTS	6 Months Ended
	Mar. 31, 2019
SUBSEQUENT EVENTS [Abstract]
SUBSEQUENT EVENTS	11 SUBSEQUENT EVENTS The Company has evaluated events that occurred subsequent to March 31, 2019 through May 15, 2019, the date these condensed consolidated financial statements were issued, for matters that required disclosure or adjustment in these condensed consolidated financial statements. It has concluded that no such events took place.

ACCOUNTING POLICIES (Policies)

ACCOUNTING POLICIES (Policies)	6 Months Ended
	Mar. 31, 2019
ACCOUNTING POLICIES [Abstract]
Basis of preparation	Basis of preparation These unaudited condensed consolidated financial statements have been prepared following the requirements of the Securities and Exchange Commission (the "SEC”) and United States generally accepted accounting principles (“GAAP”) for interim reporting. In the opinion of management, the accompanying condensed consolidated financial statements include all adjustments, which include only normal recurring adjustments, necessary to present fairly the Company’s interim financial information. The accompanying unaudited condensed consolidated financial statements should be read in conjunction with the audited financial statements as of and for the year ended September 30, 2018
Principles of Consolidation	Principles of Consolidation In accordance with Accounting Standards Codification ("ASC") 810 Consolidation, the Company consolidates any entity in which it has a controlling financial interest. Further, the Company consolidates any variable interest entity that it is deemed to be the primary beneficiary of, and for which the Company has the power to direct its significant activities. Upon review of the relationship between Rasna Therapeutics Limited (“Rasna UK”) and Rasna Inc., Management noted that equity investment in Rasna UK was not sufficient to fund its operations. Accordingly, Rasna Inc. was considered to be the primary beneficiary of the assets held within Rasna UK, which primarily consist of cash received from Rasna Inc. to fund its operations, and for which the Company has the power to direct its significant activities. As a result, Rasna Inc. consolidates this variable interest entity, which has minimal activity and is in the process of being liquidated. The consolidated financial statements include the financial statements of the Company and its subsidiary, Arna Therapeutics Limited and its variable interest entity, Rasna Therapeutics Ltd, as well as the operations of Rasna Inc. for the period from May 17, 2016 through March 31, 2019 All significant intercompany accounts and transactions have been eliminated in the preparation of the accompanying consolidated financial statements.
Business Combinations	Business Combinations Management accounts for business combinations under the provisions of ASC Topic 805 10 805 10 805 10 The amounts reflected within Note 3 are the results of the final valuation report of the purchase price allocation.
Going Concern	Going Concern The Company is subject to a number of risks similar to those of other pre-commercial stage companies, including its dependence on key individuals, uncertainty of product development and generation of revenues, dependence on outside sources of capital, risks associated with research, development, testing, and obtaining related regulatory approvals of its pipeline products, suppliers and collaborators, successful protection of intellectual property, competition with larger, better-capitalized companies, successful completion of the Company's development programs and, ultimately, the attainment of profitable operations are dependent on future events, including obtaining adequate financing to fulfill its development activities and generating a level of revenues adequate to support the Company's cost structure. The Company has experienced net losses and significant cash outflows from cash used in operating activities over the past years, and at March 31, 2019 , had an accumulated deficit of $17,042,093, a net loss for the six months ended March 31, 2019 of $666,664 and net cash used in operating activities of $100,280. We expect to continue to incur net losses and have significant cash outflows for at least the next 12 In the event that the Company is unable to secure the necessary additional cash resources needed, the Company may slow current development phases or halt new development phases in order to mitigate the effects of the costs of development. These conditions, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying condensed consolidated financial statements have been prepared assuming that the Company will continue as a going concern. This basis of accounting contemplates the recovery of the Company's assets and the satisfaction of liabilities in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of positive cash flows adequate to support the Company's cost structure.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. The Company evaluates its estimates on an ongoing basis, including those related to the fair values of stock based awards, income taxes and contingent liabilities, among others. The Company bases its estimates on historical experience and on various other assumptions that the Company believes to be reasonable, the results of which form the basis for making judgments about the carrying values of assets and liabilities. Actual results could differ from those estimates and such differences could be material to the consolidated financial position and results of operations.
Fair Value	Fair Value The carrying value of the Company’s financial instruments, including cash and cash equivalents, related party balances, accounts payable and accrued liabilities, approximate fair value because of the short-term nature of such financial instruments. Management measures certain other assets at fair value on a nonrecurring basis when they are deemed to be other-than-temporarily impaired.
Concentration of Credit Risk	Concentration of Credit Risk Financial instruments that potentially subject the Company to concentrations of credit risk consist principally of related party receivables. Deposits held with banks, including those held in foreign branches of global banks, may exceed the amount of insurance provided on such deposits. These deposits may be redeemed upon demand and bear minimal risk. Management believes that the institutions that hold our instruments are financially sound and are subject to minimal credit risk.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all short-term investment with an original maturity of three March 31, 2019 September 30, 2018 42,413 and $ respectively.
Property and Equipment	Property and Equipment Expenditures for additions, renewals and improvements are capitalized at cost. Depreciation is computed in a straight line method based on the estimated useful lives of the related assets. The estimated useful lives of the major classes of depreciable assets are 3 year s for property and equipment
Goodwill and Intangible assets	Goodwill and Intangible assets Intangible assets are made up of indefinite lived intangible assets, in-process research and development, (“IPR&D”) and certain intellectual property (“IP”). The balance of the indefinite lived intangible assets represents the platform technology that was acquired in 2013 (see Note 3 - Acquisitions) n ha Goodwill represents the premium paid over the fair value of the net tangible and intangible assets acquired in business combinations. Goodwill is not amortized; rather, it is subject to a periodic assessment for impairment by applying a fair value based test. Goodwill is assessed for impairment on an annual basis or more frequently if events or changes in circumstances indicate that the asset might be impaired. An impairment charge is recognized only when the implied fair value of the Company’s reporting unit’s goodwill is less than its carrying amount. Management evaluates indefinite life intangible assets for impairment on an annual basis and on an interim basis if events or changes in circumstances between annual impairment tests indicate that the asset might be impaired. The ongoing evaluation for impairment of its indefinite life intangible assets requires significant management estimates and judgment. Management reviews indefinite life intangible assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. There were no impairment charges during the six months ended March 31, 2019 2018
Risks and Uncertainties	Risks and Uncertainties The Company intends to operate in an industry that is subject to rapid change. The Company’s operations will be subject to significant risk and uncertainties including financial, operational, technological, regulatory, and other risks associated with an early stage company, including the potential risk of business failure.
Research and development	Research and development Expenditure for research and development are charged to the statements of operations in the year in which it is incurred with the exception of expenditures incurred in respect of the development of major new products where the outcome of those projects is assessed as being reasonably certain in regards to viability and technical feasibility. Such expenditure is capitalized and amortized straight line over the estimated period of sale for each product, commencing in the year that sales of the product are first made. To date, the Company has not capitalized any such expenditures other than certain IPR&D & IP recorded in connection with certain acquisition or equity transactions.
Foreign Currency	Foreign Currency Items included in the financial statements are measured using their functional currency, being the currency of the primary economic environment in which the company operates. The financial statements are presented in United States Dollar (“USD”), which is the company’s functional and presentational currency. Foreign currency transactions are translated using the rate of exchange applicable at the date of the transaction. Foreign exchange gains and losses resulting from the settlement of such transactions and from the re-translation at the year-end of monetary assets and liabilities denominated in foreign currencies are recognized in the statements of operations.
Net Loss per Share	Net Loss per Share Basic net loss per share is computed by dividing net loss available to common shareholders by the weighted average number of common shares outstanding during the period. Diluted loss per share includes potentially dilutive securities such as outstanding options and warrants, using various methods such as the treasury stock or modified treasury stock method in the determination of dilutive shares outstanding during each reporting period. The following table sets forth potential common shares issuable upon the exercise of outstanding options and the exercise of warrants, all of which have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: March 31, 2019 March 31, 2018 Stock options 4,076,675 4,829,875 Warrants 1,926,501 1,926,501 Total shares issuable upon exercise or conversion 6,003,176 6,756,376 The following is the computation of net loss per share for the following periods: For the Three Months Ended March 31, 2019 2018 (Unaudited) (Unaudited) Net loss for the period $ (265,360 ) $ (1,144,412 ) Weighted average number of shares 68,908,003 68,908,003 Net loss per share (basic and diluted) $ (0.00 ) $ (0.02 ) For the Six Months Ended March 31, 2019 2018 (Unaudited) (Unaudited) Net loss for the period $ (666,664 ) $ (2,867,013 ) Weighted average number of shares 68,908,003 68,908,003 Net loss per share (basic and diluted) $ (0.01 ) $ (0.04 )
Warrants	Warrants In April 2016, the Company committed to issue warrants as compensation to the placement agents relating to fundraising. On February 28, 2017, the Company issued a ten year warrant to purchase 1,440,501 shares of common stock at an exercise price of $0.37 per share. The Company had determined that the service inception date preceded the grant date, and accordingly, recorded a liability to issue warrants in the Company as of the date that the equity was issued, with an offset charge to additional paid-in capital as these are offering costs. The liability to issue warrants was marked to market each period until the grant date, at which point the Company determined that in accordance with ASC 815-40-25- 7 7 - Warrants In July 2017, the Company committed to issue warrants as compensation to the placement agents relating to fundraising. On August 31, 2017, the Company issued a ten year warrant to purchase 112,000 shares of common stock at an exercise price of $0.65 per share. On August 31, 2017, the Company entered into consulting agreements with placement agents who were providing consulting services in the areas of capital market advisory and investor relations. In lieu of fees for these consulting services, on September 1, 2017, the Company issued ten year warrants to purchase 374,000 shares of common stock at an exercise price of $0.60 per share. The Company determined that the service inception date did not precede the grant date, and accordingly classifies the warrants in shareholders' equity, in accordance with ASC 815-40-25- 7 7
Equity-Based Payments	Equity-Based Payments ASC Topic 718 The Company accounts for stock options issued and vesting to non-employees in accordance with ASC Topic 505 50
Income taxes	Income taxes On December 22, 2017, The Tax Cuts and Jobs Act was signed into law and has resulted in significant change to the U.S corporate income tax system. These changes include a federal statutory rate reduction from Changes in tax rates and tax laws are accounted for in the period of enactment. D uring the six March 31, 2019 2017
Recent Accounting Pronouncements Not Yet Adopted	Recent Accounting Pronouncements In January 2017, the FASB issued ASU 2017 1 805 The Company adopted ASU 2017 01 In January 2017, the FASB issued ASU 2017 04 350 two An entity will apply a one The guidance is effective for annual and interim goodwill impairment tests performed for periods beginning after December 15, 2019 with early adoption permitted in January 2017. The Company is currently evaluating the impact of adopting this guidance In July 2017, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2017 11 260 480 815 1 815 2 260 In August, 2016, the FASB issued ASU 2016 15 320 2016 15 eight 2016 15 In May 2017, The FASB issued ASU 2017 09 718 2017 09 2017 09 2017 09 In June 2018, the FASB issued ASU 2018 - 07 , Compensation - Stock Compensation (Topic 718 718 , to include share-based payment transactions for acquiring goods and services from nonemployees. Some of the areas for simplification apply only to nonpublic entities. The amendments specify that Topic 718 apply to all share-based payment transactions in which a grantor acquires goods or services to be used or consumed in a grantor’s own operations by issuing share-based payment awards. The amendments in A SU 2018 - 07 also clarify that Topic 718 does not apply to share-based payments used to effectively provide ( 1 ) financing to the issuer or ( 2 ) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for under Topic 606 , Revenue from Contracts with Customers. The amendments in this Update are effective for public business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. Early adoption is permitted. We do not plan to early adopt this ASU. We are currently evaluating the potential impacts of this updated guidance, and do not expect the adoption of this guidance to have a material impact on our consolidated financial statements and related disclosures. In August 2018, the FASB issued ASU 2018 13 820 2018 13

ACCOUNTING POLICIES (Tables)

ACCOUNTING POLICIES (Tables)	6 Months Ended
	Mar. 31, 2019
ACCOUNTING POLICIES [Abstract]
Schedule of potential common shares issuable upon the exercise of outstanding options and the exercise of warrants	The following table sets forth potential common shares issuable upon the exercise of outstanding options and the exercise of warrants, all of which have been excluded from the computation of diluted weighted average shares outstanding as they would be anti-dilutive: March 31, 2019 March 31, 2018 Stock options 4,076,675 4,829,875 Warrants 1,926,501 1,926,501 Total shares issuable upon exercise or conversion 6,003,176 6,756,376
Schedule of computation of net loss per share	The following is the computation of net loss per share for the following periods: For the Three Months Ended March 31, 2019 2018 (Unaudited) (Unaudited) Net loss for the period $ (265,360 ) $ (1,144,412 ) Weighted average number of shares 68,908,003 68,908,003 Net loss per share (basic and diluted) $ (0.00 ) $ (0.02 ) For the Six Months Ended March 31, 2019 2018 (Unaudited) (Unaudited) Net loss for the period $ (666,664 ) $ (2,867,013 ) Weighted average number of shares 68,908,003 68,908,003 Net loss per share (basic and diluted) $ (0.01 ) $ (0.04 )

ACQUISITIONS (Tables)

ACQUISITIONS (Tables)	6 Months Ended
	Mar. 31, 2019
ACQUISITIONS [Abstract]
Schedule of allocation of the purchase price in connection with the acquisition	The Company’s allocation of the purchase price in connection with the acquisition was calculated as follows: Balance as of May 17, 2016 Share consideration transferred $ 7,675,000 Forgiveness of receivable 607,159 Consideration transferred $ 8,282,159 Less: Fair value of assets acquired Cash and cash equivalents (5,116,609 ) Other receivables (14,187 ) Prepayment (66,856 ) Related party receivables (20,412 ) Intellectual property (236,269 ) In-Process research and development (613,100 ) Plus: Liabilities assumed Accounts payable and accrued expenses 492,603 Related party payables 15,656 Goodwill $ 2,722,985

GOODWILL AND INTANGIBLE ASSETS

GOODWILL AND INTANGIBLE ASSETS (Tables)	6 Months Ended
	Mar. 31, 2019
GOODWILL AND INTANGIBLE ASSETS [Abstract]
Summary of goodwill	The following table summarizes the Company’s goodwill for the periods indicated resulting from the acquisitions by the Company: March 31, September 30, 2019 2018 Goodwill $ 2,722,985 $ 2,722,985
Summary of intangible assets	The following table summarizes the Company’s intangible assets as of the following periods: March 31, September 30, 2019 2018 Estimated (Unaudited) Useful Life In-process research and development $ 613,100 $ 613,100 Indefinite Intellectual Property 236,269 236,269 Indefinite Indefinite lived intangible asset 1,300,000 1,300,000 Indefinite $ 2,149,369 $ 2,149,369

ACCOUNTS PAYABLE AND ACCRUED _2

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)	6 Months Ended
	Mar. 31, 2019
ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]
Accounts Payable and Accrued Expenses	The following table summarizes the Company’s accounts payable and accrued expenses as of the following periods: March 31, 2019 (Unaudited) September 30, 2018 Accounts payable $ 829,903 $ 719,830 Accrued expenses 752,865 701,825 $ 1,582,768 $ 1,421,655

STOCK-BASED COMPENSATION (Table

STOCK-BASED COMPENSATION (Tables)	6 Months Ended
	Mar. 31, 2019
STOCK-BASED COMPENSATION [Abstract]
Summary of stock option activity	The following table summarizes stock option activity for the three months ended March 31, 2019 Number of Options Weighted Average Exercise Price Per Option Weighted Average remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding balance at September 30, 2018 4,819,875 0.55 7.27 $ 589,837 Granted — — — — Exercised — — — — Forfeited and Expired (743,200 ) (0.30 ) — — Outstanding balance at March 31, 2019 4,076,675 0.59 6.87 $ — Options exercisable at March 31, 2019 2,539,796 0.40 6.2 $ —

WARRANTS (Tables)

WARRANTS (Tables)	6 Months Ended
	Mar. 31, 2019
WARRANTS [Abstract]
Summary of warrant activity	The following table summarizes warrant activity for the six months ended March 31, 2019 Number of Warrants Weighted Average Exercise Price Per Option Weighted Average remaining Contractual Life (years) Aggregate Intrinsic Value Outstanding balance at September 30, 2018 1,926,501 — — 6,875,819 Granted — — — — Forfeited — — — — Outstanding balance at March 31, 2019 1,926,501 — — $ 6,875,819 Warrants exercisable at March 31, 2019 — — — $ —

GENERAL INFORMATION (Details)

GENERAL INFORMATION (Details)	Apr. 27, 2016USD ($)
Falconridge Holdings Limited | Rasna DE
Organization, Consolidation and Presentation of Financial Statements [Line Items]
Consideration transferred	$ 1

ACCOUNTING POLICIES - Narrativ

ACCOUNTING POLICIES - Narrative (Details) - USD ($)	Dec. 22, 2017	Sep. 01, 2017	Aug. 31, 2017	Feb. 28, 2017	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Sep. 30, 2018	Sep. 30, 2017
Accounting Policies [Line Items]
Accumulated deficit					$ (17,042,093)		$ (17,042,093)		$ (16,375,429)
Net Loss					(265,360)	$ (1,144,412)	(666,664)	$ (2,867,013)
Net cash used in operating activities							(100,280)	(1,994,145)
Cash and cash equivalents					$ 42,413	$ 539,393	$ 42,413	$ 539,393	$ 42,693	$ 2,537,611
Useful life							3 years
Impairment charge							$ 0
Federal statutory rate	35.00%				21.00%
Placement Agent
Accounting Policies [Line Items]
Warrant term		10 years	10 years	10 years
Warrant to purchase number of shares (in shares)		374,000	112,000	1,440,501
Exercise price (in dollars per share)		$ 0.60	$ 0.65	$ 0.37

ACCOUNTING POLICIES - Antidilu

ACCOUNTING POLICIES - Antidilutive Shares (Details) - shares	3 Months Ended	6 Months Ended
	Mar. 31, 2018	Mar. 31, 2019
Accounting Policies [Line Items]
Total shares issuable upon exercise or conversion	6,756,376	6,003,176
Warrants
Accounting Policies [Line Items]
Total shares issuable upon exercise or conversion	1,926,501	1,926,501
Stock options
Accounting Policies [Line Items]
Total shares issuable upon exercise or conversion	4,829,875	4,076,675

ACCOUNTING POLICIES - Net Loss

ACCOUNTING POLICIES - Net Loss per Share (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018
ACCOUNTING POLICIES [Abstract]
Net loss for the period	$ (265,360)	$ (1,144,412)	$ (666,664)	$ (2,867,013)
Weighted average number of shares (in shares)	68,908,003	68,908,003	68,908,003	68,908,003
Net loss per share (basic and diluted) (in dollars per share)	$ 0	$ (0.02)	$ (0.01)	$ (0.04)

ACQUISITIONS - Narrative (Deta

ACQUISITIONS - Narrative (Details)	Aug. 15, 2016shareholdershares	May 17, 2016USD ($)$ / sharesshares	Mar. 31, 2019shares	Sep. 30, 2018shares	May 05, 2016USD ($)
Business Acquisition [Line Items]
Related party receivable forgiven | $		$ 607,159
Indefinite-lived intangible asset | $		613,100
Shares outstanding (in shares)			68,908,003	68,908,003
IPR&D
Business Acquisition [Line Items]
Indefinite-lived intangible asset | $		$ 613,100
Active With Me, Inc.
Business Acquisition [Line Items]
Shares issued (in shares)	3,305,000
Cancellation of shares (in shares)	1,500,000
Shares issued in exchange (in shares)	0.33
Number of legacy shareholders with canceled shares following Merger | shareholder	1
Reverse stock split	3.25 for 1
Shares outstanding (in shares)	64,679,798
Active With Me, Inc. | Post Merger
Business Acquisition [Line Items]
Shares cancelled as result of split-off (in shares)	1,500,000
Shares outstanding (in shares)	19,901,471
Arna Therapeutics Limited
Business Acquisition [Line Items]
Voting interests acquired (as percent)		65.00%
Share price (in dollars per share) | $ / shares		$ 0.40
Shares issued (in shares)		19,187,500
Shares issuable pursuant to acquisition (in shares)		54,837,790
Consideration transferred | $		$ 7,675,000
Rasna, Inc.
Business Acquisition [Line Items]
Consideration transferred | $		8,282,159
Rasna, Inc. | IPR&D
Business Acquisition [Line Items]
Indefinite-lived intangible asset | $		$ 613,100
Falconridge Holdings Limited
Business Acquisition [Line Items]
Notes payable | $					$ 236,269

ACQUISITIONS - Allocation of P

ACQUISITIONS - Allocation of Purchase Price (Details) - USD ($)	May 17, 2016	Mar. 31, 2019	Sep. 30, 2018
Less: Fair value of assets acquired
Indefinite-lived intangible asset	$ (613,100)
Plus: Liabilities assumed
Goodwill		$ 2,722,985	$ 2,722,985
In-process research and development
Less: Fair value of assets acquired
Indefinite-lived intangible asset	(613,100)
Rasna, Inc.
Business Acquisition [Line Items]
Share consideration transferred	7,675,000
Forgiveness of receivable	607,159
Consideration transferred	8,282,159
Less: Fair value of assets acquired
Cash and cash equivalents	(5,116,609)
Other receivables	(14,187)
Prepayment	(66,856)
Related party receivables	(20,412)
Plus: Liabilities assumed
Accounts payable and accrued expenses	492,603
Related party payables	15,656
Goodwill	2,722,985
Rasna, Inc. | Intellectual property
Less: Fair value of assets acquired
Indefinite-lived intangible asset	(236,269)
Rasna, Inc. | In-process research and development
Less: Fair value of assets acquired
Indefinite-lived intangible asset	$ (613,100)

GOODWILL AND INTANGIBLE ASSET_2

GOODWILL AND INTANGIBLE ASSETS - Narrative (Details)	Dec. 17, 2013USD ($)project$ / sharesshares	Mar. 31, 2019USD ($)	Mar. 31, 2019USD ($)	Sep. 30, 2018USD ($)	May 17, 2016EUR (€)	May 17, 2016USD ($)	Jan. 01, 2015EUR (€)	Oct. 31, 2013$ / shares
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs						$ 613,100
Goodwill		$ 2,722,985	$ 2,722,985	$ 2,722,985
Goodwill impairment		$ 0		0
Number of independent research projects | project	2
Impairment charge			$ 0	$ 0
IPR&D
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs						613,100
Price per share (in dollars per share) | $ / shares	$ 0.13
Shares issued (in dollars per share) | $ / shares	$ 0.28							$ 0.13
Indefinite-lived intangible asset acquired	$ 1,300,000
IPR&D | Eurema Consulting S.r.l.
Indefinite-lived Intangible Assets [Line Items]
Stock issued (in shares) | shares	5,000,000
IPR&D | TES Pharma S.r.l.
Indefinite-lived Intangible Assets [Line Items]
Stock issued (in shares) | shares	5,000,000
Clinical Research Organization | IPR&D
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs | €							€ 100,002
Amended License Agreement | IPR&D
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs | €					€ 435,000
Rasna, Inc.
Indefinite-lived Intangible Assets [Line Items]
Goodwill						2,722,985
Rasna, Inc. | Intellectual property
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs						236,269
Rasna, Inc. | IPR&D
Indefinite-lived Intangible Assets [Line Items]
IPR&D costs						$ 613,100

GOODWILL AND INTANGIBLE ASSET_3

GOODWILL AND INTANGIBLE ASSETS - Goodwill (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
GOODWILL AND INTANGIBLE ASSETS [Abstract]
Goodwill	$ 2,722,985	$ 2,722,985

GOODWILL AND INTANGIBLE ASSET_4

GOODWILL AND INTANGIBLE ASSETS - Intangible Assets (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
Indefinite-lived Intangible Assets [Line Items]
Intangible assets	$ 2,149,369	$ 2,149,369
In-process research and development
Indefinite-lived Intangible Assets [Line Items]
Intangible assets	613,100	613,100
Intellectual Property
Indefinite-lived Intangible Assets [Line Items]
Intangible assets	236,269	236,269
Indefinite lived intangible asset
Indefinite-lived Intangible Assets [Line Items]
Intangible assets	$ 1,300,000	$ 1,300,000

ACCOUNTS PAYABLE AND ACCRUED _3

ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Summary of Accounts Payable and Accrued Expenses (Details) - USD ($)	Mar. 31, 2019	Sep. 30, 2018
ACCOUNTS PAYABLE AND ACCRUED EXPENSES [Abstract]
Accounts payable	$ 829,903	$ 719,830
Accrued expenses	752,865	701,825
Accounts payable and accrued expenses	$ 1,582,768	$ 1,421,655

ACCOUNTS PAYABLE AND ACCRUED _4

ACCOUNTS PAYABLE AND ACCRUED EXPENSES - Narrative (Details) - USD ($)	12 Months Ended
	Sep. 30, 2018	Mar. 31, 2019
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expenses	$ 701,825	$ 752,865
Accrual for director fees		202,000
Payroll accruals		22,000
Legal expenses		146,000
Travel expenses incurred credit card expenses	39,000	44,000
Accrued legal, accounting and professional fees	72,000
Research and development expense	193,000
Payroll related expenses	22,000
Directors fees	165,000
Consultancy and legal fees	155,000
Patent related expenses	$ 55,000
Other accrued costs		71,000
Vendors for research and development expenses
Accounts Payable and Accrued Liabilities [Line Items]
Accrued expenses		$ 268,000

STOCK-BASED COMPENSATION - Nar

STOCK-BASED COMPENSATION - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2019	Mar. 31, 2018	Mar. 31, 2019	Mar. 31, 2018	Jul. 19, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options granted (in shares)
2016 Equity Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized (in shares)					9,750,000
Total unrecognized compensation cost related to stock options	$ 342,523		$ 342,523
Weighted average period to costs are expected to be recognized over			6 months 29 days
General and Administrative Expense
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	(107,140)	$ 240,050	$ (226,157)	$ 492,959
Consultancy Fees Third Parties
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation	$ (14,689)	$ 0	$ (5,470)	$ 31,471

STOCK-BASED COMPENSATION - Sto

STOCK-BASED COMPENSATION - Stock Options (Details) - USD ($)	6 Months Ended	12 Months Ended
	Mar. 31, 2019	Sep. 30, 2018
Number of Options
Number of Options, Outstanding balance (in shares)	4,819,875
Number of Options, Granted (in shares)
Number of Options, Exercised (in shares)
Number of Options, Forfeited and Expired (in shares)	(743,200)
Number of Options, Outstanding balance (in shares)	4,076,675	4,819,875
Number of Options, Options exercisable (in shares)	2,539,796
Weighted Average Exercise Price Per Option
Weighted Average Exercise Price Per Option, Outstanding balance (in dollars per share)	$ 0.55
Weighted Average Exercise Price Per Option, Granted (in dollars per share)
Weighted Average Exercise Price Per Option, Exercised (in dollars per share)
Weighted Average Exercise Price Per Option, Forfeited and Expired (in dollars per share)	(0.30)
Weighted Average Exercise Price Per Option, Outstanding balance (in dollars per share)	0.59	$ 0.55
Weighted Average Exercise Price Per Option exercisable (in dollars per share)	$ 0.40
Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]
Weighted Average remaining Contractual Life (years), Outstanding balance	6 years 10 months 13 days	7 years 3 months 7 days
Weighted Average remaining Contractual Life (years) Options exercisable	6 years 2 months 12 days
Aggregate Intrinsic Value Outstanding balance		$ 589,837
Aggregate Intrinsic Value Options exercisable

WARRANTS - Narrative (Details)

WARRANTS - Narrative (Details) - USD ($)	Sep. 01, 2017	Apr. 10, 2016	Mar. 31, 2019	Mar. 31, 2019	Mar. 31, 2018
Class of Warrant or Right [Line Items]
Warrants issued for consulting services					$ 522,350
Warrant [Member]
Class of Warrant or Right [Line Items]
Warrants issued for consulting services		$ 484,009
Warrants provided for services, period for issue	6 months
Costs recognized			$ 0	$ 0

WARRANTS - Summary of Warrant A

WARRANTS - Summary of Warrant Activity (Details) - Warrant [Member]	6 Months Ended
	Mar. 31, 2019USD ($)$ / sharesshares
Number of Warrants
Outstanding	1,926,501
Granted
Forfeited
Outstanding	1,926,501
Warrants exercisable
Weighted Average Exercise Price Per Option
Granted | $ / shares
Forfeited | $ / shares
Outstanding | $ / shares
Warrants exercisable | $ / shares
Aggregate Intrinsic Value
Outstanding | $	$ 6,875,819
Granted | $
Outstanding | $	6,875,819
Warrants exercisable | $

CONVERTIBLE NOTE (Details)

CONVERTIBLE NOTE (Details) - Convertible Debt [Member] - USD ($)	1 Months Ended	6 Months Ended	12 Months Ended
	Oct. 19, 2018	Mar. 31, 2019	Sep. 30, 2018	Aug. 08, 2018
Debt Instrument [Line Items]
Interest rate (as percentage)	12.00%	12.00%		12.00%
Cash received from the Holder	$ 100,000		$ 135,000
Due Date		Aug. 9, 2019
Conversion price		$ 0.65
Period after the date of the Agreement used to calculate the conversion price		180 days
Shares reserved for the conversion of the Notes		1,566,667

RELATED PARTY TRANSACTIONS - N

RELATED PARTY TRANSACTIONS - Narrative (Details) - USD ($)	6 Months Ended
	Mar. 31, 2019	Sep. 30, 2018
Related Party Transaction [Line Items]
Balance due to related party	$ 550,000	$ 550,000
Interest expense	0
Eurema Consulting S.r.l.
Related Party Transaction [Line Items]
Due from related party	200,000	200,000
Gabriele Cerrone
Related Party Transaction [Line Items]
Balance due to related party	175,000	175,000
Roberto Pellicciari
Related Party Transaction [Line Items]
Balance due to related party	175,000	175,000
Tiziana Life Sciences PLC
Related Party Transaction [Line Items]
Due from related party	76,900	252,746
Panetta Partners
Related Party Transaction [Line Items]
Due from related party	0	0
Alessandro Padova
Related Party Transaction [Line Items]
Due from related party	$ 75,000	$ 75,000

COMMITMENTS AND CONTINGENCIES -

COMMITMENTS AND CONTINGENCIES - Narrative (Details)	May 24, 2017USD ($)	Feb. 28, 2018USD ($)	Jun. 30, 2017USD ($)$ / sharesshares	Apr. 30, 2017USD ($)	Nov. 30, 2016EUR (€)	Oct. 31, 2016USD ($)	Mar. 31, 2019USD ($)	Mar. 31, 2019USD ($)$ / sharesshares	Mar. 31, 2018USD ($)
Options granted (in shares) | shares
Exercise price of options granted (in dollars per share) | $ / shares
Bucks County Biotechnology Centre Inc. | Lease agreement
Future minimum payments due		$ 13,480
Estimated utility expense per month		$ 237
Rent expense								$ 8,000
License Agreement
Amount payable for making milestone | €					€ 50,000
Agreement term					6 months
Employment and Consultancy Agreements | Chief Financial Officer
Officer's compensation				$ 80,000		$ 50,000
Consultancy expenses								20,000
Prepaid Officers Compensation							$ 6,666	6,666
Employment and Consultancy Agreements | Chief Executive Officer
Officer's compensation	$ 300,000
Performance bonus (as percent)	35.00%
Bonus accrued							0	0
Salary expenses							0	0
Employment and Consultancy Agreements | Dr. Shailubhai
Options granted (in shares) | shares			1,700,000
Vesting period			4 years
Exercise price of options granted (in dollars per share) | $ / shares			$ 0.85
Grant date fair value			$ 985,081
Expenses related to options								69,576	$ 140,700
Shared Services Agreement | Tiziana Life Sciences PLC
Due to affiliates							$ 76,900	$ 76,900